Candel Therapeutics Inc (CADL)

Candel Therapeutics, Inc. (CADL), headquartered in Needham, Massachusetts, is a leading clinical-stage biotechnology company, committed to developing advanced oncolytic viral immunotherapies for cancer patients. Emphasizing on creating an innovative patient-centric therapeutic approach, the company focuses on comprehending and decoding the complex interactions between tumor cells and the immune system.

Since its inception, Candel has deliberately curated an expansive pipeline of viral immunotherapies in conjunction with its leading-edge Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform. These products target a diverse range of large market, solid tumor indications and have been employed in early and late-stage clinical trials with over 600 patients, showing impressive responses across a broad range of cancers. The most advanced programs are CAN-2409 for newly diagnosed glioblastoma, a type of brain cancer, and CAN-3110 for prostate cancer, both currently in Phase 3 studies.

Candel Therapeutics' immuno-oncology approach uses GMCI™, which involves the delivery of a non-replicating viral vector encoding for the enzyme, herpes simplex virus thymidine kinase. This leads to localized production of the protein, which generates a comprehensive immune response both locally and systemically. This process essentially changes the entire tumor into a vaccine, producing an immune response that can eliminate residual disease and prevent cancer recurrence.

Additionally, Candel Therapeutics' pipeline includes next-generation viral immunotherapies. They are developing these therapies for various types of cancers including pancreatic, lung, and colorectal. These deliver multiple immune-stimulating genes directly into the tumor, aiming to generate a more robust immune response.

As a biotechnology leader, the company has created an expansive intellectual property portfolio providing protection for its GMCI™ platform and product candidates. Candel Therapeutics, Inc. is committed to improving patient outcomes by advancing cutting-edge immunotherapies in oncology, enabling a future where cancer treatments are more efficient, effective, and accessible. Supported by its strong scientific acumen and dedicated team, the company continuously endeavors to expand the horizons of cancer therapeutics.

Overall, Candel Therapeutics, Inc. is a precision medicine-focused entity, at the forefront of exploring and developing innovative technologies to challenge and change the existing paradigms of cancer care. Its dedication to research, testing and therapeutic implementation is not just propelling the company forward, but also contributing to progress in the broader biotech and healthcare sector.